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ABSTRACT
In this dissertation work, the drug Aceclofenac is tried to micro encapsulated with two
different polymers such as ethyl cellulose, polyvinyl pyrrolidone. Microcapsules were
prepared by solvent evaporation method using an acetone / liquid paraffin system, in
which the drug particles are dispersed in a polymeric solution which is emulsified into
external phase containing emulsifier [Span 80]. For each polymer the microcapsule
preparations are done in three different ratios of drug to the polymer. A key variable
for successful microencapsulation was the selection of proper type and concentration
of the emulsifier. The results showed that the Ethylcellose and Polyvinyl pyrrolidone
are able to microencapsulate the drug. The drug-loaded microcapsules showed highest
encapsulation efficiency with 1:1 drug to polymer ratio in case of  Ethyl  cellulose
microcapsules  and  1:2  ratio  in  case  of  polyvinylpyrrolidone   microcapsules.  The
expected reason for this difference in release rate between ratios of same polymeric
microcapsules was based on the particle size and size distribution of microcapsules.
The infrared spectra thermographs showed stable character of Aceclofenac in drug-
loaded  microcapsules  and  revealed  the  absence  of  drug-polymer  interactions.
Microscopic study revealed that the Ethylcellulose microcapsules were spherical in
nature and Polyvinyl pyrrolidone microcapsules were mostly irregular in nature.
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1. INTRODUCTION
An ideal dosage regimen in the drug therapy of any disease is the one which
immediately  attains  the  desired  therapeutic  concentration  of  drug  in  plasma  and
maintains it constant for the entire duration of treatment.   This is possible through
administration of a conventional dosage form in a particular frequency and dose.1  But
the dosing interval is shorter than half-life of drug resulting in a number of limitations
such as – 
1. Poor patient compliance.
2. Unavoidable fluctuations in drug concentration in blood.
3. Fluctuations  may  lead  to  adverse  effects  especially  of  a  drug  with  small
therapeutic index.
4. Peak valley plasma drug level is obtained which makes attainment of steady
state condition difficult.
There are two ways to overcome such a situation –
1. Development  of  new, better  and safer  drugs with long half-lives and large
therapeutic indices, and
2. Effective  and  safer  use  of  existing  drugs  in  the  form  of  controlled  drug
delivery systems.
The  first  approach  has  many  disadvantages  which  therefore  resulted  in
increased interest in the second approach.  An ideal controlled drug delivery system is
one which delivers the drug at a pre-determined rate, locally or systematically, for a
specified period of time.
In general, controlled delivery attempts to – 
1. Sustain drug action at a predetermined rate by maintaining a constant blood
level of the drug.
2. Localize  drug  action  by  spatial  placement  of  controlled  released  system
adjacent to the diseased tissue.
3. Targeting drug action by using carriers.
There are three types of controlled drug delivery systems, namely
i) Passive Preprogrammed, in which the release rate is predetermined and is
irresponsive to the external biological environment.
ii) Active Preprogrammed,  in  which  the  release  rate  can  be  altered  by  the
external source.
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iii) Active self-programmed, in which the release rate is depend on response to
information, registered by a sensor, on the changing biological environment
such as blood sugar level.
The several  advantages of  controlled drug  delivering system over  a  conventional
dosage form are – 
1. Improved patient convenience and compliance.
2. Reduction  in  fluctuation  in  steady  state  level  of  drug,  so  therefore  better
control of disease. 
3. Increased safety margin of highly potent drugs.
4. Maximum utilization of drugs.
5. Reduction in health care costs.
Disadvantages of control release dosage form include -
1. Decreased systemic availability due to incomplete release, increased first pass
metabolism, increased instability,  in sufficient resistance time for complete
release, site specific absorption, etc.
2. Poor in vitro – in vivo correlation.
3. Possibility of dose dumping.
4. Retrieval of drug is difficult in case of toxicity.
5. Higher cost of formulation.
The controlled drug delivery Systems (CDDS) are mainly administered as:
 
Oral Ingestion has long been the most convenient and commonly employed
route  of  drug  delivery.   Indeed,  for  sustained  release  system  the  oral  route  of
administration has received most attention with respect to research on physiological
and drug constraints as well as design and testing of products.  This is because there is
more flexibility  in  dosage  form design  for  the oral  route than  these three  for  the
parenteral route.
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The following are the different oral sustained drug delivery systems:
a. Dissolution control release.
b. Diffusion control release.
c. Diffusion and Dissolution control release.
d. Ion-Exchange resins.
e. pH-independent formulations.
f. Osmotically controlled release.
g. Altered density formulations.
Microencapsulation techniques are the one of the methods used to prepare the
above two controlled release systems like diffusion controlled release and dissolution
controlled release.
MICROPARTICLES2
These are the particles with size more than ‘1’µm, containing the polymer.  At
present, there is no universally accepted size range that particles must have in order to
be classified as microparticles.  However, many workers classify the particles smaller
than ‘1’µm, as nanoparticles and those more than 1000 µm as macroparticles.
Classification – Microparticles are classified into two groups,
MICROSPHERES
Microspheres  are  solid,  spherical  particles  containing  dispersed  drug
molecules, either in solution or crystalline form, among the polymer molecules.
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TYPES OF MICROCAPSULES
MICROCAPSULES
Solid Core                                                              Liquid Core
(Protective or release controlling coating)
Continuous/ shell        Multinuclear                      Non-permeable,       Semi-permeable
Microcapsule              Microcapsule                       rigid membrane        membrane
                                                                                    coating                      coating
                                                              Continuous / Shell           Multinuclear 
                                                              Microcapsule                   Microcapsule
Continuous/Shell
Multinuclear
                                                                                   Microcapsule           Microcapsule
Microcapsules  have  an  either  spherical  geometry  with  a  continuous  core
region surrounded by a continuous shell or have an irregular geometry and contain a
number of small droplets.
CRITERIA FOR COATING MATERIALS3
The coating materials should meet the following ideal criteria.
1. Capable of forming a film that is cohesive with the core material.
2. Chemically compatible and non-reactive with the core material.
3. Provide  the  desired  coating  properties  such  as  strength,  flexibility,
impermeability, optical properties and stability.
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METHOD OF MICROCAPSULES PREPARATION
There are two types of process to prepare microcapsules. 
TYPE – A (CHEMICAL) PROCESS
1. Coacervation – Phase separation. 
2. Interfacial polymerization.
3. In-situ polymerization.
4. Solvent evaporation.
5. Solvent extraction.
TYPE – B (MECHNAICAL) PROCESS
1. Spray drying.
2. Fluidized Bed coating.
3. Multiorifice – centrifugal processes.
4. Pan coating.
TYPE ‘A’ PROCESS
Solvent – Evaporation Method
(Emulsification – evaporation Method)
This  technique  is  based  on  the  evaporation  of  the  internal  phase  of  an
emulsion  by  agitation.   Initially,  the  coating  polymeric  material  is  dissolved  in  a
volatile organic solvent.  The core to be encapsulated is then dispersed in the coating
polymer solution to form a suspension or emulsion.
In  the  next  step,  this  organic  solution  is  emulsified  under  agitation  in  a
dispersing phase, which is immiscible with the organic solvent, which contains the
emulsifier.  Once the emulsion is stabilized, agitation is maintained and the solvent
evaporates after diffusing through the continuous phase.  This results in the formation
of  microcapsule.   On  the  completion  of  the  process,  the  microcapsules  held  in
suspension in the continuous phase are recovered by filtration or centrifugation and
are washed and dried.
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   Core material dispersed Dispersing (aqueous)
                        in organic solution of coating           media with Emulsifier
    Coating polymer 
Formation of emulsion
Under mechanical stirring
                       Evaporation of Formation of Solid
                       Organic solvent Microcapsules
Solvent evaporation technique is basically divided into ‘3’ different types of
techniques – 
i.    Oil in Water Emulsion
In  this  system,  the  polymer  is  dissolved  in  an  organic  solvent  such  as
Dichloromethane or  Chloroform.   The active principle/core  dispersed in  the same
medium and then the entire mixture is emulsified in an aqueous solution containing
emulsifier.
Factors governing the Encapsulation efficiency of drug –
a. Partition coefficient -  The  partitioning  phenomena  operates
between the dispersed and the dispersing phases which contributes to
a substantial lowering of microencapsulation efficiency.
b. Degree of ionization.
Strategy for improving Encapsulation Efficiency of Drug – 
a. Water solubility of the drug can be reduced by chemical modification prior
to its incorporation in the organic phase.
However,  such  structural  modification  may  give  rise  to  toxicological
problems.
b. Modifying the dispersing phase of the emulsion to reduce leakage of the
drug from oily droplets of polymer solution.
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Modifications like,
a. Saturating the continuous phase with the drug
b. Adjusting the pH of this same phase
c. Adding the elctrolytes
However the validity and effectiveness of these strategies vary from case to
case.  For example, chemical modification only concern to a limited number of active
substances, and the saturation of external phase is only of value for low water soluble
drugs or inexpensive drugs. Similarly, if the adjusting of pH can prove advantageous
for  ionization drugs,  this procedure  generally  accelerates  the degradation  of  some
polymers.
ii.   Multiple Emulsion : w/o/w
In these systems, active principles to be encapsulated are incorporated in an
aqueous solution, which is poured into a casting organic solution of the polymer to
form an emulsion of the type w/o.  This primary emulsion is itself emulsified in an
external aqueous phase leading to a multiple emulsion of the type w/o/w, the organic
phase  acts  as  a  barrier  between  the  two  aqueous  compartments  preventing  the
diffusion of the medicine towards the aqueous phase.
Advantage – This process is more effective when the water solubility of the
drug is high and partitioning between the organic phase is disfavourable.
Application –  This  process  is  used  for  encapsulation  of  drug  which  are
strongly water soluble.
iii.  Non-aqueous Emulsion : o/o emulsion
This technique is similar to o/w emulsion evaporation but dispersing medium
can be constituted by a mineral or vegetable or a non-volatile organic solvent.
Advantage – This technique prevent hydrolysis of some drug
Disadvantage – This technique often expensive and need to be recycled.
7
Mechanism of Solvent Evaporation Method
This system is  characterized  by the existence  of  several  interfaces  through
which mass transfer occurs during particle formation, as shown in the below in figure.
 
Simple Emulsion                                             Multiple Emulsion
                   (o/w or o/o)                                                      (w/o/w)
Figure 1
Organic solvent of the dispersed phase of the emulsion is eliminated in two stages– 
1. Diffusion of the solvent in the dispersing phase
2. Elimination of the solvent at dispersing phase – air interface
The formation of solid microcapsule is brought about by the evaporation of the
volatile solvent L1 the interface L2/G.   During the course of solvent evaporation, a
partitioning  is  produced  across  the  interface  L1 /  L2 from the  dispersed  phase  to
continuous phase leading to the formation of solid microcapsules.
Solvent – Extraction Method
As mentioned in the previous method, the organic solvent of the dispersed
phase of the emulsion is eliminated in two stages, i.e.
i.  Diffusion into continuous phase, and 
ii. Elimination of solvent at continuous phase – air interface
If one uses a continuous phase which will immediately extract the solvent of
the  dispersed  phase,  the  evaporation  stage  is  no  longer  necessary  in
microencapsulation.
In practice it is achieved
a. by using large volume of dispersing phase w.t.o dispersed phase. Or
b. by choosing a cosolvents in dispersed phase, of which at least one has a great
affinity for the dispersing phase. Or 
c. by formulating a dispersing phase with two solvents in which one acts as a
solvent extractor of the dispersed phase.
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TYPE ‘B’ PROCESSES
1. Spray Drying
In this process dispersing the core material in a liquefied coating substance and
spraying  this  mixture  into  such  an  environment  condition  where  by  relatively
rapid solidification of the coating is effected.
Advantage – Low cost  of encapsulation and able to produce large amount  of
microcapsules.
Disadvantage – This process is limited to coating material soluble in water, but
the list of water soluble coating materials are limited.
2. Fluidized bed coating (Wurster Air Suspension)
It consists of the dispersing of solid core materials in a supporting air stream and
then spray coating of the air suspended particles.
Advantage – Able to handle an extremely wide range of coating formulations.
3. Multi orifice – Centrifugal Processes
In this process it utilizes centrifugal forces to hurl a core material particle through
an  enveloping  microencapsulating  membrane,  thereby  affecting  mechanical
microencapsulation.
4. Pan Coating
The coating material solution is applied as a solution to the solid core material in a
coating pan.
POLYMERS USED FOR MICROENCAPSULATION3
I. Water Soluble resins
• Gelatin
• Gum Arabic
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• Starch
• Polyvinyl pyrrolidone
• Sodium carboxy methyl cellulose
• Hydroxy ethyl cellulose
• Methyl cellulose
• Arabinogalactam
• Polyvinyl alcohol
• Polyacrylic acid
II. Water Insoluble resins
• Ethyl cellulose
• Polymethyl methacrylate (PMMA)
• Polymethacrylate (Eudragit)
• Polyethylene
• Polyamide (Nylon)
• Poly (Ethylene-vinyl acetate)
• Cellulose nitrate
• Silicones
• Poly(lactide-co-glycolide)
• Cellulose acetate butyrate
III. Waxes and Lipids
• Paraffin
• Carnauba Wax
• Spermaceti
• Bees Wax
• Stearic Acid
• Stearyl Alcohol
• Glyceryl Stearates
IV. Enteric Resins
• Shellac
• Cellulose acetate phthalate
• Zein
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MECHANISM OF DRUG RELEASE FROM MICROCAPSULES4
In  the  controlled  release  of  drug  from  polymer-membrane  permeation
controlled  drug  delivery  system,  the  drug  particles  are  visualized  as  not  being
releasable from the device until the drug molecules on the outer most surface layer of
a drug practice dissociate from their crystal lattice structure dissolve or partition into
the surrounding polymer (in membrane), diffuse through it and finally partition into
the elution medium surrounding drug delivery system.
This mechanistic analysis suggests that the solubility of a drug species in a
rate-controlling membrane plays a rate controlling role in its release from a polymeric
device.   To  release  at  an  appropriate  rate  the  drug  requires  adequate  polymer
solubility.
FACTOR INFLUENCING THE DESIGN OF ORAL SUSTAINED RELEASE
PRODUCTS1, 5
A.  Physicochemical Properties of Drug
i.    Aqueous Solubility
      Drugs with good aqueous solubility are the good candidates for oral
sustained  drug delivery system (SDDS).   Whereas  drugs  with very low solubility
(<0.01 mg/ml) are inherently sustained, since their release over the time course of a
dosage form in the G.I.T will be limited by dissolution of drug.
ii.   Partition Coefficient (PKo/w)
Drugs with extremely high PKo/w readily penetrate the biological membrane but are
unable to  proceed  further,  while  drugs  with excessive  aqueous  solubility,  i.e.  low
Pko/w
 
cannot penetrate the membrane.  Hence a balance in the PKo/w is needed.
iii.  Drug Stability
      Drugs that are unstable in the stomach can be placed in a slowly soluble
form or have their release delayed until they reach the small intestine. However, such
a strategy would be detrimental for drug that either unstable in the small intestine or
undergo extensive gut-wall metabolism, as evidenced by reduced bioavailability when
these drugs are administered from a SDDS.
iv.  Protein Binding
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     If the drugs are having high degree of blood protein binding, then they are
serve as a depot for drug producing a prolonged release profile.
B.  Pharmacokinetic Characteristics of the Drug
i.   Absorption
    Drug for an oral SDDS its absorption rate must be efficient since the desired
rate limiting step is rate of drug release Kr, i.e. Kr <<Ka.   A drug with slow absorption
is a poor candidate for SDDS.
ii.  Elimination of half-life 
     Drug with half-life in the range of 2-4 hrs make good candidates for such a
system.  For drugs with t ½ less than ‘2’ hrs, a very large dose may be required to
maintain the high release rate.  Similarly drugs with long t ½ need to be presented in
such a formulation.
iii.  Metabolism
       Drug which is extensively metabolized is suitable for SDDS as long as the
rate  of  metabolism  is  not  too  rapid.   A  drug  capable  of  inducing  or  inhibiting
metabolism is a poor candidate for SDDS.  Since steady state blood level would be
difficult to maintain.
iv. Dosage Form Index
      It is the ratio of CSS,max to CSS,min.  Since the goal of controlled release
formulation  is  to  improve  therapy  by  reducing  the  dosage  form  index  while
maintaining the plasma level within the therapeutic window, ideally its value should
be closed one. 
C.  Pharmacodynamic Characteristics of the Drug33, 34
i.  Therapeutic Range
     Drugs for SDDS should have a wide therapeutic range.
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ii.  Plasma Drug Concentration – Response Relationship
     Drug whose pharmacological activity is independent of its concentration
are poor candidates for SDDS.
2. LITERATURE REVIEW
 Ruiz, J.M. developed the procedure for the micro-encapsulation of peptide, a
study  of  the  phase-separation  of  poly(D,L-Lacto  acid-Co-glycolic  acid)  co-
polymers 50/50 by silicon oil.12
 Chowdary, K.P.R. demonstrated microencapsulation by calcium alginate.  The
evaluation of release kinetics suggested that all the microcapsules were found to
be discrete spherical and free flowing.13
13
 Pitchaimani,  R. shown  comparative  evaluation  of  Norfloxacin  containing
microcapsules by coacervation phase separation method.   The release kinetics
from the  cellulose  acetate  micro  capsules  was found to  be  slower  than  that
obtained from gelatin microcapsules.14
 Chowdary,  K.P.R.  prepared the  microcapsules  of  Nifedipine  by  solvent
evaporation method.  The release depended on proportion of MCC in Solvent
deposited systems used as core, coat, core ratio and size of microcapsules.15
 Gohel,  M.C.  prepared  Diclofenac  sodium microspheres  by emulsion solvent
evaporation technique.  The stirring speed, polymer to drug ratio, concentration
of ethyl cellulose solution and type of solvent were found to influence the in
vitro drug release from the microspheres.16
 Doshi, C.C. prepared the levonorgestrel loaded biodegradable microspheres by
emulsion solvent evaporation technique.  The release kinetic of LNG from the
microspheres  was  observed  to  be  dependent  on  the  ethanol  content  of  the
dissolution media.17
 Hoffart,  V.  demonstrated  micro-encapsulation  of  low  molecular  weight
Heparin.  They shown encapsulation efficiency and release rate strongly depend
on distribution of drug.18
 Youan  Celestin  Bi-Botti.  developed  micro-encapsulation  of  superoxide
dismutase by reverse micelle solvent evaporation.  This formulation allowed the
in vitro release of superoxide dismutase for at least 72 hrs.19
 Chowdary, K.P.R. prepared the mucoadhesive microcapsules of Indomethacin
by  emulsification-ionic  gelation  process.    They  showed  drug  release  was
diffusion controlled and followed first order kinetics.20
 Hasan, N.Y. demonstrated stability indicating methods for the determination of
Aceclofenac.  Applciation of the proposed methods could be applied as stability
indicating methods for the determination of pure aceclofenac and in presence of
diclofenac either in the bulk powder or in pharmaceutical formulation.21
 Fulzele,  S.V.  prepared  and evaluated microcapsules  using polymerized  resin
and developed the in vitro dissolution study confirmed the Higuchi-order release
pattern.22
 Acuna,  J.A. developed  the  polarographic  behaviour  of  Aceclofenac  in  a
methanol-water mixture. 23
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 Assimopoulou, A.N. prepared the alkanin containing microcapsules by solvent
evaporation  method  and  studied  the  high  release  rate  and  a  great  extent  of
particle size of alkanin microencapsulation.24
 Murthy, T.E.G.K. developed the formulation and evaluation of Ethyl cellulose-
coated diclofenac sodium microcapsules and studied diclofenac release from the
microcapsule was followed first order kinetics and influenced by the size of the
microcapsules.  Among the solvent employed chloroform was found to be more
suitable for slow release of diclofenac from ethyl cellulose microcapsules.25
 Sahoo, S. K. prepared stavudine by solvent evaporation method and studied that
the best fit release kinetics was achieved with Higuchi plot followed by Zero
order and first order.  The release of stavudine was influenced by the drug to
polymer ratio and particle size was found to be diffusion controlled.26
 Gowda,  K.V.  demonstrated  the  evaluation  of  bioequivalence  of  two
formulations  containing  100  mg  of  aceclofenac  and  suggested  that  90%
confidence interval for the ratio of the logarithmic transformed AUCo-t, AUCo-∞
and Cmax were within the bioequivalence limit 0.80 – 1.25.27
 Bolourtchian, N. studied on microencapsulation of Ibuprofen and discussed its
characterization.28
 Yang, C. demonstrated the microencapsulation of Aspirin with Ethylcellulose
by solvent evaporation method.29
 Sajeev, C. prepared oral controlled release formulation of Diclofenac sodium by
microencapsulation using Ethylcellulose.30
 Rolland  et  al studied  the  characterization  of  microspheres  using  different
drugs.31
 Dorle, A. K. studied microencapsulation using Eudragit polymer.32
 Patel,  J.  K. reported  formulation and  evaluation  of  mucoadhesive  Glipizide
microspheres.39
 Shanmugum, S. reported analysis method for Aceclofenac.40
 Mahaparale, P. R. reported analytical methods for estimation of Aceclofenac
with Paracetamol in tablet dosage form.41
 Geetharao, C. G. reported studies on microspheres as targeting and controlled
release.42
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3. DRUG & POLYMER PROFILE
3.1. DRUG PROFILE6, 7
1. Aceclofenac:
A. Physio-chemical Properties of the drug – 
1. Description
a. Nomenclature
i.   Chemical name 
A phenyl acetic acid derivative
   (2-{(2, 6-dichlorophenyl) amino} Phenyl acetoxy acetic acid) 
16
ii. Generic name 
    Aceclofenac
b. Molecular weight and Formula
Molecular weight = 354.19
2. Appearance, Colour
A white or almost white crystalline powder
3. Solubility
Solvent Solubility
Alcohol Soluble
Acetone Freely soluble
Water Practically insoluble
Dichloromethane Sparingly soluble
2 Pharmacokinetic Properties38
i.    Oral absorption - Rapidly absorbed
ii.   Bioavailability - Almost 100%
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COOH
ONH
O
Cl
iii.   Distribution - Highly protein – bound (>99.7%)
iv.   Elimination      -The mean plasma elimination half life is 4-4.3 hours.
Clearance is  estimated to 5 litres per hour.   Approx.
two-third of the administered dose is excreted via the
urine, mainly as conjugated hydroxymetabolites.  Only
1%  of  an  oral  single  dose  is  excreted  unchanged.
Aceclofenac is probably metabolized via CYP2C9 to
the main metabolite 4-hydroxy-Aceclofenac.
v.    Dose    - Maximum recommended dose is 200 mg daily takes as
two separate 100 mg doses, one tablet in the morning
and one in the evening.    Aceclofenac  can be taken
before or after food.
vi. Therapeutic Indication - Symptomatic treatment of pain and inflammation
of  post  traumatic  pain,  cervical  pain  and  low  back
pain.
3 Pharmacodynamic Properties35
a.  Category 
 A novel non-steroidal anti-inflammatory drug.
b.  Mechanism of Action 
Aceclofenac is a novel NSAID known to exhibit multifactor mechanism of
action.    Aceclofenac  was  developed  in  order  to  provide  a  highly  effective  pain
relieving  therapy  with  a  reduced  side-effect  profile,  especially  GI  events  that  are
frequently experienced with NSAID therapy.
a.   Aceclofenac directly blocks PGE2 secretion at the site of inflammation by
inhibiting  IL-Beta  and  TNF  in  the  inflammatory  cells  (Intracellular
action).
b. Aceclofenac  stimulates  the  synthesis  of  the  extracellular  matrix  of  the
Human Articular cartilages.
c. Aceclofenac  inhibits  Neutrophil  Adhesion  and  Accumulation  at  the
inflammatory site in the early phase and thus blocks the pro-inflammatory
actions of Neutrophils.
d. Aceclofenac is  also an NSAID with a  greater  COX-2 specificity when
compared to Diclofenac sodium.
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c.   Adverse effects
a. Mild to moderate liver cirrhosis
b. Renal impairment (mild to moderate)
3.2. POLYMER PROFILE8
1. Ethyl Cellulose
i. Chemical name - Cellulose ethyl ether
ii. Description - It is a white, tasteless, free flowing powder
iii. Functional category - Coating agent, tablet binder, tablet filler
iv. Solubility                  - Practically insoluble in water, freely soluble in 
                                         Chloroform, soluble in dichloromethane
v. Applications - It is a good polymer which is more suitable in
sustained Release formulation of most of the drug
      - It is water impermeable in nature
- For microencapsulation it is used in concentration of
10 to 20% (w/v)
- Ethyl cellulose coating is used to modify the release
of a  drug, to improve the stability of a formulation.
2. Poly-vinyl pyrolidone (PVP)
i. Functional category - Coating agent, tablet binder, tablet filler
ii. Solubility - Soluble in acetone
iii. Application - PVP is used as a poreformer in the microcapsules due
to its water permeability nature
4. OBJECTIVE
The goal of therapy for any disease is to provide and enhance the patient well-
beingness with least or no local systemic side effects after the administration of the
drug.  Unfortunately many of the administered conventional dosage forms will causes
local or systemic side effects and unavoidable fluctuations in blood level of the drug.
As a result  it  is difficult  to achieve such a goal  of therapy and this leads to poor
patient compliance.  To overcome such a problem and to improve patient compliance
controlled release drug delivery systems was developed.
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The main objective of the present studies is an effort to prolong the action of
the drug Aceclofenac by formulating in microcapsules  drug delivery system using
different polymers and to explore suitability of the polymer for the same. 
5. PLAN OF WORK
1. Preformulation studies.
     i) Physical appearance.
    ii) Characterization of drug. 
• UV Spectrum
• IR Spectrum 
    iii) Scanning and preparation of standard curve by Spectrophotometeric method.
   
2. Preparation of Aceclofenac micro-capsules using different polymers such as – 
i. Ethyl Cellulose
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         ii. Poly Vinyl Pyrrolidone
3. Evaluation of Aceclofenac microcapsules, such as 
i. Determination of drug encapsulation efficiency
ii. In vitro dissolution studies
iii. Particle size and shape determination
iv. Drug – polymer compatibility study
- FTIR Study
6.  EXPERIMENTAL WORK
6.1. PREFORMULATION STUDIES:
6.1.1.  Physical appearance: 
 Aceclofenac is a white or almost white crystalline powder.
6.1.2. Characterization of drug:
Ultraviolet spectroscopy test:
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50mg of the drug was dissolved in methanol and diluted to 100ml with the
same solvent. 2ml of the solution was diluted to 50ml with methanol. Then it was
examined between 220nm and 370nm wavelength. The solution showed an absorption
maximum at 275nm. The specific absorbance at the maximum is 320-350nm.
Fig. 2:  UV SPECTRUM OF ACECLOFENAC IN METHANOL
Infrared spectroscopy test:
The infrared spectrum of potassium bromide dispersion of Aceclofenac is in
accordance with the reference spectrum.
SOLVENT CONCENTRATION λ max (in nm) ABSORBANCE
Methanol 20 275.2 0.695
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Fig. 3:  IR SPECTRA OF ACECLOFENAC WITH MAJOR PEAKS AT
3333.10, 2935.76, 1720.56, 1523.36, 1313.57, 850.64
6.1.3. Scanning of the drug:
Aceclofenac was scanned in these solvents – 
a. Methanol
b. Phosphate buffer (pH 7.2)
Scanning of Drug in Methanol
Aceclofenac  was  scanned  in  methanol  as  per  European  –  Pharmacopoeial
method. 10 mg of drug was dissolved in 100 ml of methanol.  This gave the solution
concentration of 100 mcg/ml used as a stock solution. Then it was further diluted to
30mcg/ml. The prepared solution was scanned in the UV region from 220-370 nm. A
characteristic peak was observed at 275 nm.
 Scanning of the Drug in phosphate buffer pH 7.2
10 mg of drug was dissolved in 100 ml of phosphate buffer pH 7.2.  This gave
the solution concentration of 100 mcg/ml used as a stock solution. Then it was further
diluted to 30mcg / ml.  The prepared solution was scanned in the UV region from
220-370 nm.  A characteristic peak was observed at 275.4 nm.
6.1.4. Standard plot of drug with solvent methanol36
Accurately weighed 10 mg of drug was dissolved in 100ml of methanol. Then
diluting it 2.5, 5, 7.5, 10, 12.5, 15 to 50ml respectively. This gave the concentration of
5,  10,  15,  20,  25;  30mcg/ml  and the  absorbance  were  taken  against  the  λmax at
275nm. 
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Concentration
(mcg/ml)
Average
Absorbance
5 0.147
10
0.293
15 0.458
20 0.653
25 0.807
  (Each absorbance were taken in triplicate)
Standard Plot of Drug with phosphate buffer (pH 7.2) 
 Accurately weighed 10mg of drug was dissolved in 100ml phosphate buffer.
Then  diluting  it  2.5,  5,  7.5,  10,  12.5,  15  ml  to  50ml respectively.  This  gave  the
concentration of 5, 10, 15, 20, 25, 30 mcg/ml and the absorbance were taken against
the λmax 275.4 nm. 
Concentration
(mcg/ml)
Average
Absorbance
5 0.136
10 0.275
15 0.392
20 0.508
25 0.635
24
30 0.764
   (Each absorbance were taken in triplicate)
By regression analysis, Correlation coefficient R2 = 0.9992
Instruments and equipments used:
• Shimadzu UV-Pharmaspec 1700: UV Visible spectrophotometer.
• Mettler Toledo, Semi Micro Analytical balance. Model- AB104-s
• Systronics,µ-pH Meter, Model-361
• Magnetic Stirrer, Indian Equipment Corporation, Mumbai.
• FTIR, Shimadzu-Prestige-21.
• Lab India dissolution apparatus.
• Leica-DMF Microscope.
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6.2. PREPARATION OF ACECLOFENAC MICROCAPSULES37
1.  Materials 
a) Aceclofenac obtained as a gift sample from IPCA Laboratories Ltd., Mumbai.
b) Ethyl cellulose 
c) Polyvinyl pyrrolidone
d) Methanol 
e) Dichloromethane
f)    Acetone
g)  Light liquid paraffin
h)  Cyclohexane
i)     Span 80
2.  Method (Solvent evaporation method)  
(i) Procedure 
Different  amount  of  polymer  was  dissolved  in  a  solvent  (acetone)  using
magnetic stirrer, to form a homogeneous polymer solution. The drug was dispersed in
the polymer solution. The resulting dispersion was then poured in to the mixture of
light liquid paraffin,  cyclohexane and Span 80, while stirring.  A mechanical stirrer
was used for stirring. Stirring (at 800 to 1000 rpm) was continued for 3 hrs., until  the
solvent  evaporated  completely.  After  evaporation  of  solvent,  the  microcapsules
formed were filtered using Whatmann filter paper (No. 1 grade).  The residue was
washed with 4 - 5 times in 50 ml cyclohexane each. Micro capsules were dried in
desiccators for 24 hrs. 
(ii) Formulation
Table 1:  Formulation of Microencapsulation of Aceclofenac
S.No.
Ratio
Drug :
Polymer
Type of
Polymer
Drug
(mg)
Amount
of
Polymer
Solvent
Acetone(ml)
Polymer
conc. in
solvent
(% w/v)
External
phase
1 1:1 Ethyl
cellulose
500 500 10 5 Liquid
paraffin
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2 1:2 -do- 500 1000 10 10
3 1:3 -do- 500 1500 10 15
4 1:2 PVP 500 1000 10 10
5 1:3 -do- 500 1500 10 15
6 1:4 -do- 500 2000 10 20
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S.No.
Ratio
Drug :
polymer
Solvent
Concentration of
polymer in
solvent
(% w/v)
External
phase Emulsifier
Emulsifier
concentration
( %v/v) Result
Micro
encapsulation
efficiency
(% w/v)
        (± S.D)
1 1:6
Acetone
30
Liquid
paraffin Span 80
1.96 Failure …………..
2 1:4 20 1.96 Failure …………..
3 1:3 15 1.96 Encapsulated 80.40±0.9848
4 1:2 10 1.96 Encapsulated 94.45±0.901
5 1:1 5 1.96 Encapsulated 96.01±0.115
6 1:1 5 1.96 Failure …………..
6.3. TRIALS:-
Table2:   DIFFERENT TRIALS FOR MICRO-ENCAPSULATION WITH ETHYL CELLULOSE
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Above mentioned all the trials were done in triplicate batches
Table 3:  DIFFERENT TRIALS FOR MICRO-ENCAPSULATION WITH POLYVINYL PYRROLIDONE (PVP)
S.No.
Ratio
Drug :
polymer
Solvent
Concentration of
polymer in
solvent
(% w/v)
External
phase Emulsifier
Emulsifier
concentration
( %v/v) Result
Micro
encapsulation
efficiency
(% w/v)
        (± S.D)
1 1:1
Acetone
5
Liquid
paraffin Span 80
0.99 Failure …………..
2 1:2 10 0.99 Encapsulated 92.5±1.135
3 1:3 15 0.99 Encapsulated 60.1±1.153
4 1:4 20 0.99 Encapsulated 46.44±0.787
5 1:6 30 0.99 Failure …………...
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6.4. EVALUATION OF ACECLOFENAC MICROCAPSULES
i. Determination of Encapsulation efficiency of microcapsules:
Accurately weighed microcapsules containing 5mg equivalent amount of Aceclofenac
was  dissolved  in  the  50ml  methanol  and  shaken  vigorously.  Then  undissolved
particles are removed by filtering through Whatmann filter paper. Finally 5 ml of this
solution is diluted to 50 ml with respective blank solution and then its UV absorbance
is to be noted.
Then the encapsulation efficiency is calculated by using the given below equation
Encapsulation efficiency =            x 100
                                                 
ii. Dissolution Rate study: 
The in-vitro release studies of microcapsules were carried out at 37±1ºc temperature
and 100 rpm using phosphate buffer pH 7.2 in USP dissolution test apparatus (type
II). Accurately weight samples of microcapsules (containing approximately 50 mg of
drug) are taken in the muslin cloth ant tied properly to the paddles of the dissolution
test  apparatus,  USP.  900  ml  of  dissolution  media  were  used  for  analysis.  The
microcapsules were added to dissolution medium and at present time intervals 5 ml
aliquots  were  withdrawn  and  replaced  by  an  equal  volume  of  fresh  dissolution
medium. Then it  was further  diluted up to 10 ml by taking 2ml of sample.  After
suitable dilution the sample were analyzed spectrophotometrically at 275.4 nm.
iii. Particle size analysis:  
The prepared microcapsules were examined by optical  microscopy using eye-piece
micrometer. The eye-piece is calibrated with the help of stage micrometer. The mean
diameter  and  particle  size  distribution  of  each  formulation  were  measured  by
determination of the martin’s diameter of 100 randomly selected particles.
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Actual drug content     
Theoretical drug content
iv. Drug-Polymer Compatibility Study
Drug-polymer compatibility is a critical parameter or factor to evaluate the efficiency
of a formulation. For a stable and effective formulation, the drug-polymer interaction
should  be  least.  Despite  of  all  the  methods  used  for  evaluation  of  drug-polymer
interaction studies; the following two methods have been employed.
FT-IR spectroscopy: In this method the spectra were recorded for pure drug and drug
loaded  microcapsules  using  the  instrument  IR-Prestige-21,  Shimadzu,  Japan,
employing  KBr  disc  method.  The  scanning  range  was  400-4000  cm-1 and  the
resolution was 1 cm-1.
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7. RESULTS AND DISCUSSIONS
7.1 Characterization of bulk drug:
Supplied drug Aceclofenac passed the test for identification and analysis. 
7.2 Preparation of microcapsule:
Ethylcellulose  polymer  was able  to  microencapsulate  the drug  Aceclofenac  when  the
solvent for polymeric solution was acetone and external phase is containing Span 80 as
an  emulsifier.  Also  Ethylcellulose  was  able  to  encapsulate  the  drug  when  the
concentration of the polymer was (5-15) % w/v in solvent. 
The PVP polymer  was able to  microcapsulate  the drug when the external  phase was
containing liquid  paraffin.  However,  the  PVP was  able  to  encapsulate  the  drug  only
above 10% w/v and unable to encapsulate below it i.e 10% w/v.
7.3 Morphological  and  Microscopic  characterization  of
Microcapsules:
A. Morphological characterization:
The Ethylcellulose microcapsules were freely flowing, white colored particles whereas
PVP microcapsule were slightly aggregated particles.
B. Microscopic characterization:
The prepared Ethylcellulose microcapsules with different drug to polymer ratio (1:1, 1:2,
1:3)  were  uniform and  almost  spherical  in  appearance,  whereas,  PVP  microcapsules
using drug to polymer ratio (1:2, 1:3) were spherical but 1:4 ratio was mostly irregular.
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Fig. 4: Photograph of Ethylcellulose Microcapsules with drug:polymer ratio 1:1
Fig. 5: Photograph of Ethylcellulose Microcapsules with drug:polymer ratio 1:1
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Fig. 6: Photograph of Ethylcellulose Microcapsules with drug:polymer ratio 1:2
Fig. 7: Photograph of Ethylcellulose Microcapsules with drug:polymer ratio 1:3
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Fig. 8: Photograph of PVP Microcapsules with drug:polymer ratio 1:2
Fig. 9: Photograph of PVP Microcapsules with drug:polymer ratio 1:3
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Fig. 10:  Photograph of PVP Microcapsules with drug:polymer ratio 1:4
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7.4 IN VITRO DISSOLUTION STUDIES
DISSOLUTION TEST—1
Polymer: Ethyl Cellulose
Ratio: 1:1 Apparatus: Paddle with muslin cloth
Polymer concentration: 5% (w/v) R.P.M: 100
Encapsulation efficiency: 96.0165% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
1. 100mg Temperature: 37±1oC
2. 100mg
3. 100mg 
Sampling volume = 5ml
Table 4: Results of Dissolution Test-1
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul. %
release
Mean±
S.D.
1
0.092 0.00653 5.87857 - 5.87857 6.97381±
2.67388
7.26362±
2.785000.08 0.00557 5.02142 - 5.021420.15 0.01113 10.0214 - 10.0214
2
0.342 0.02637 23.7357 0.03265 23.7683 22.6077±
1.03245
23.5473±
1.075360.321 0.02470 22.2357 0.02789 22.26360.314 0.02415 21.7357 0.05567 21.7913
3
0.452 0.03510 31.5928 0.16452 31.7573 31.7807±
0.80918
33.1015±
0.842810.464 0.03605 32.45 0.15142 32.60140.441 0.03423 30.8071 0.17642 30.9835
4
0.52 0.0405 36.45 0.34004 36.7900 36.9564±
0.22334
38.4922±
0.232620.526 0.04097 36.8785 0.33170 37.21020.521 0.04057 36.5214 0.34757 36.8690
6
0.669 0.05232 47.0928 0.54254 47.6354 48.1125±
0.95769
50.1117±
0.997490.667 0.05216 46.95 0.53658 47.48650.691 0.05407 48.6642 0.55047 49.2147
8
0.805 0.06311 56.8071 0.80416 57.6113 58.2336±
0.55470
60.6537±
0.577750.82 0.06431 57.8785 0.79742 58.67590.816 0.06399 57.5928 0.82083 58.4136
10
0.96 0.07542 67.8785 1.11976 68.9983 69.8622±
0.76378
72.7655±
0.795530.976 0.07669 69.0214 1.11896 70.14040.98 0.07700 69.3071 1.14079 70.4479
12
1.123 0.08835 79.5214 1.49686 81.0182 81.4821±
0.968412
84.8684±
1.0086571.145 0.090103 81.09286 1.502421 82.595281.12 0.088119 79.30714 1.525833 80.83298
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DISSOLUTION TEST— 2
Polymer: Ethyl Cellulose
Ratio: 1:2 Apparatus: Paddle with muslin cloth
Polymer concentration: 10% (w/v) R.P.M: 100
Encapsulation efficiency: 94.454% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
4. 100mg Temperature: 37±1oC
5. 100mg
6. 100mg 
Sampling volume = 5ml
Table 5: Results of Dissolution Test-2
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul.
% release
Mean±
S.D.
1
0.0968 0.006913 6.221429 - 6.221429 5.95238±
0.466004
6.3021±
0.4933870.0855 0.006016 5.414286 - 5.4142860.0968 0.006913 6.221429 - 6.221429
2
0.344 0.026532 23.87857 0.034563 23.91313 23.1259±
0.682799
24.4848±
0.7229210.327 0.025183 22.66429 0.030079 22.694370.328 0.025262 22.73571 0.034563 22.77028
3
0.4 0.030976 27.87857 0.167222 28.04579 30.3494±
2.69979
32.1328±
2.8584340.474 0.036849 33.16429 0.155992 33.320280.423 0.032802 29.52143 0.160873 29.6823
4
0.52 0.0405 36.45 0.322103 36.7721 36.9457±
0.239377
39.1167±
0.2534440.526 0.040976 36.87857 0.340238 37.218810.521 0.040579 36.52143 0.324881 36.84631
6
0.769 0.060262 54.23571 0.524603 54.76032 53.8158±
0.896023
56.9781±
0.9486740.754 0.059071 53.16429 0.545119 53.70940.744 0.058278 52.45 0.527778 52.97778
8
0.906 0.071135 64.02143 0.825913 64.84734 64.5166±
1.23724
68.3076±
1.3099420.882 0.06923 62.30714 0.840476 63.147620.916 0.071929 64.73571 0.819167 65.55488
10
1.06 0.083357 75.02143 1.181587 76.20302 75.4180±
4.096422
79.8497±
4.3371331.1 0.086532 77.87857 1.186627 79.06520.987 0.077563 69.80714 1.17881 70.98595
12
1.2123 0.095444 85.9 1.598373 87.49837 85.8852±
2.74811
90.9319±
2.9095921.145 0.090103 81.09286 1.619286 82.712141.212 0.095421 85.87857 1.566627 87.4452
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DISSOLUTION TEST— 3
Polymer: Ethyl Cellulose
Ratio: 1:3 Apparatus: Paddle with muslin cloth
Polymer concentration: 15% (w/v) R.P.M: 100
Encapsulation efficiency: 80.4086% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
7. 100mg Temperature: 37±1oC
8. 100mg
9. 100mg 
Sampling volume = 5ml
Table 6: Results of Dissolution Test-3
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul.
%
release
Mean±
S.D.
1
0.079 0.0055 4.95 4.95 7.49761±
3.525659
9.32539±
4.3850940.094 0.00669 6.021429 6.0214290.171 0.012802 11.52143 11.52143
2
0.263 0.020103 18.09286 0.0275 18.12036 18.4678±
1.029679
22.9696±
1.2806790.284 0.02177 19.59286 0.033452 19.626310.256 0.019548 17.59286 0.064008 17.65687
3
0.416 0.032246 29.02143 0.128016 29.14944 31.9749±
2.499506
39.7693±
3.1087990.468 0.036373 32.73571 0.142302 32.878020.482 0.037484 33.73571 0.161746 33.89746
4
0.502 0.039071 35.16429 0.289246 35.45353 36.3422±
0.887108
45.2012±
1.1033540.514 0.040024 36.02143 0.324167 36.34560.526 0.040976 36.87857 0.349167 37.22774
6
0.605 0.047246 42.52143 0.484603 43.00603 45.1614±
2.426671
56.1702±
3.018210.628 0.049071 44.16429 0.524286 44.688570.671 0.052484 47.23571 0.554048 47.78976
8
0.786 0.061611 55.45 0.720833 56.17083 54.7427±
3.289359
68.087±
4.0911910.798 0.062563 56.30714 0.769643 57.076790.712 0.055738 50.16429 0.816468 50.98075
10
0.825 0.064706 58.23571 1.028889 59.2646 59.9950±
1.099414
74.6197±
1.3674130.827 0.064865 58.37857 1.08246 59.461030.852 0.066849 60.16429 1.095159 61.25944
12
0.971 0.076294 68.66429 1.352421 70.01671 68.7271±
1.249375
85.4804±
1.553930.951 0.074706 67.23571 1.406786 68.64250.935 0.073437 66.09286 1.429405 67.52226
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DISSOLUTION TEST— 4
Polymer: Poly vinyl pyrrolidone
Ratio: 1:2 Apparatus: Paddle with muslin cloth
Polymer concentration: 10% (w/v) R.P.M: 100
Encapsulation efficiency: 92.50% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
10. 100mg Temperature: 37±1oC
11. 100mg
12. 100mg 
Sampling volume = 5ml
Table 7: Results of Dissolution Test-4
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul.
%
release
Mean±
S.D.
1
0.087 0.006135 5.521429 - 5.521429 6.85476±
2.753785
7.41047±
2.9770330.08 0.005579 5.021429 - 5.0214290.15 0.011135 10.02143 - 10.02143
2
0.292 0.022405 20.16429 0.030675 20.19496 18.0118±
1.894987
19.472±
2.0486120.248 0.018913 17.02143 0.027897 17.049330.244 0.018595 16.73571 0.055675 16.79139
3
0.352 0.027167 24.45 0.142698 24.5927 23.5641±
1.111903
25.4744±
1.2020440.34 0.026214 23.59286 0.12246 23.715320.321 0.024706 22.23571 0.148651 22.38437
4
0.4285 0.033238 29.91429 0.278532 30.19282 31.4466±
1.169494
33.9960±
1.2643050.4491 0.034873 31.38571 0.253532 31.639250.461 0.035817 32.23571 0.272183 32.5079
6
0.589 0.045976 41.37857 0.444722 41.82329 42.2484±
0.630384
45.6734±
0.6814890.591 0.046135 41.52143 0.427897 41.949330.605 0.047246 42.52143 0.45127 42.9727
8
0.805 0.063119 56.80714 0.674603 57.48175 55.5283±
1.781043
60.0299±
1.9254310.772 0.0605 54.45 0.658571 55.108570.756 0.05923 53.30714 0.6875 53.99464
10
0.953 0.074865 67.37857 0.990198 68.36877 71.6902±
3.913883
77.5020±
4.2311790.986 0.077484 69.73571 0.961071 70.696791.06 0.083357 75.02143 0.983651 76.00508
12
1.22 0.096056 86.45 1.364524 87.81452 87.4878±
0.286564
94.580±
0.3097961.214 0.095579 86.02143 1.348492 87.369921.212 0.095421 85.87857 1.400437 87.27901
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DISSOLUTION TEST— 5
Polymer: Poly vinyl pyrrolidone
Ratio: 1:3 Apparatus: Paddle with muslin cloth
Polymer concentration: 15% (w/v) R.P.M: 100
Encapsulation efficiency: 60.10% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
13. 100mg Temperature: 37±1oC
14. 100mg
15. 100mg 
Sampling volume = 5ml
Table 8: Results of Dissolution Test-5
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul.
%
release
Mean±
S.D.
1
0.074 0.00510 4.59285 - 4.59285 5.11666±
0.57735
8.51358±
0.960640.09 0.00637 5.73571 - 5.735710.08 0.00557 5.02142 - 5.02142
2
0.173 0.01296 11.6642 0.02551 11.6898 13.1450±
1.67624
21.8720±
2.789080.188 0.01415 12.7357 0.03186 12.76750.219 0.01661 14.95 0.02789 14.9779
3
0.286 0.02192 19.7357 0.09031 19.8260 19.5989±
1.22599
32.6105±
2.039930.298 0.02288 20.5928 0.10261 20.69540.264 0.02018 18.1642 0.11095 18.2752
4
0.359 0.02772 24.95 0.19996 25.1499 25.9453±
1.24170
43.1702±
2.066060.361 0.02788 25.0928 0.21702 25.30980.39 0.03018 27.1642 0.21186 27.3761
6
0.487 0.03788 34.0928 0.33857 34.4314 33.1121±
1.16306
55.0950±
1.935220.456 0.03542 31.8785 0.35642 32.2350.462 0.03589 32.3071 0.36277 32.6692
8
0.534 0.04161 37.45 0.52797 37.9779 37.508±
0.45765
62.4099±
0.761480.527 0.04105 36.95 0.53353 37.48350.521 0.04057 36.5214 0.54226 37.0636
10
0.566 0.04415 39.7357 0.73603 40.4717 39.9995±
0.59009
66.5549±
0.981840.562 0.04383 39.45 0.73881 40.18880.55 0.04288 38.5928 0.74515 39.3380
12
0.568 0.04431 39.8785 0.95678 40.8353 42.5985±
1.528633
70.8795±
2.5434820.606 0.04732 42.5928 0.95797 43.55080.604 0.04716 42.45 0.95956 43.40956
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DISSOLUTION TEST— 6
Polymer: Poly vinyl pyrrolidone
Ratio: 1:4 Apparatus: Paddle with muslin cloth
Polymer concentration: 20% (w/v) R.P.M: 100
Encapsulation efficiency: 46.44% Volume: 900ml
Micro capsules weight: Media: Phosphate buffer (pH 7.2)
16. 100mg Temperature: 37±1oC
17. 100mg
18. 100mg 
Sampling volume = 5ml
Table 9: Results of Dissolution Test-6
TIME
(hrs)
Absorbance
(A1,A2,A3)
Concn
(mg/ml)
Amount
of drug
release
in 900
ml (mg)
Corrn
factor
(mg)
Cumul.
amount
of drug
release
(mg)
Cumul.
release
(mg)
Mean±
S.D.
Cumul.
%
release
Mean±
S.D.
1
0.039 0.0023 2.0928 - 2.0928 2.045±
0.8581
4.404±
1.84780.026 0.0013 1.1643 - 1.16420.050 0.0032 2.8785 - 2.8785
2
0.081 0.0057 5.0928 0.0116 5.1044 5.604±
0.4346
12.067±
0.93590.091 0.0065 5.8071 0.0064 5.81360.092 0.0065 5.8785 0.0159 5.8945
3
0.098 0.0070 6.3071 0.0399 6.3470 6.492±
0.2442
13.980±
0.52590.104 0.0075 6.7357 0.0387 6.77440.098 0.0070 6.3071 0.0486 6.3557
4
0.122 0.0089 8.0214 0.0749 8.0963 8.433±
0.6381
18.158±
1.37410.137 0.0101 9.0928 0.0761 9.16900.121 0.0088 7.9500 0.0837 8.0336
6
0.179 0.0134 12.0928 0.1195 12.2123 11.765±
0.4267
25.334±
0.91890.167 0.0125 11.2357 0.1266 11.36230.172 0.0129 11.5928 0.1278 11.7207
8
0.221 0.0168 15.0928 0.1867 15.2795 15.615±
0.4089
33.625±
0.88050.224 0.0170 15.3071 0.1890 15.49620.232 0.0176 15.8785 0.1922 16.0708
10
0.279 0.0214 19.2357 0.2705 19.5062 19.629±
0.1138
42.269±
0.24510.281 0.0215 19.3785 0.2741 19.65270.282 0.0216 19.4500 0.2804 19.7304
12
0.327 0.0252 22.6642 0.3774 23.0417 23.784±
0.6448
51.216±
1.38850.342 0.0264 23.7357 0.3817 24.11750.343 0.0265 23.8071 0.3885 24.1956
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Table 10 :  DISSOLUTION PROFILE OF FORMULATIONS
Figure 11:  DISSOLUTION PROFILE OF FORMULATIONS
TIME
(IN HRS)
CUMULATIVE % OF DRUG RELEASED
F1 F2 F3 F4 F5 F6
0 0 0 0 0 0 0
1 7.26362 6.302 9.325 7.41 8.513 4.404
2 23.5473 24.484 22.969 19.472 21.872 12.067
3 33.1015 32.132 39.769 25.474 32.61 13.98
4 38.4922 39.116 45.201 33.996 43.17 18.158
6 50.1117 56.978 56.17 45.673 55.095 25.334
8 60.6537 68.3076 68.087 60.029 62.409 33.62
10 72.765 79.8497 74.619 77.502 66.554 42.269
12 84.8684 90.9319 85.48 94.58 70.879 51.216
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The percentage release of the drug from microcapsules formulated using different drug to
polymer ratios was calculated using the following formula:
      Cumulative amount of drug release
Percentage release = X 100
       Encapsulation efficiency
Table 11: Results of Dissolution test for microcapsules prepared using different
Drug-Polymer ratio.
S.
No
Type of
Polymer
Ratio
(Drug:
Polymer)
Time (hrs.)
for 50%
release
Time (hrs.) for
75% release
Time (hrs.) for
90% release
1 ……… 1:0(Pure Drug) ……. …… 0.75±0.000
2
3
4
Ethylcellulose
-do-
-do-
1:1
1:2
1:3
6.58±2.567
6.05±1.167
6.21±1.727
9.88±0.560
9.09±2.638
9.32±1.519
11.85±1.073
10.90±1.567
11.18±2.878
5
6
7
PVP
-do-
-do-
1:2
1:3
1:4
6.39±1.046
7.01±0.532
6.86±1.061
9.59±0.206
10.51±0.516
10.29±1.782
11.51±1.303
12.61±0.642
12.35±1.361
Note:  All the ratios were done in triplicate batches.
Calculations for above results:-
The above time taken for 50% or 75% or 90% release of drug is 
determined by y = mx + c, 
Where, m = slope of the respective dissolution release rate curve.
             C = intercept of the respective dissolution release rate curve
7.5   DRUG RELEASE KINETIC MODEL
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The following are the tables for determining the kinetic model of release of the drug from
microcapsules.
Table 12: Drug released kinetic model of Ethyl cellulose Microcapsules (1:1 Ratio)
Figure 12: Drug released kinetic model of Ethyl cellulose Microcapsules (1:1 Ratio)
Table 13: Drug released kinetic model of Ethyl cellulose Microcapsules (1:2 Ratio)
45
S.
No.
Time
(hrs)
Square
route of
Time
% Drug
Released
% Drug
Unreleased
Log %
Drug
Unreleased
Cube root
of %Drug
Unreleased
1 0 0 0 100 2 4.641589
2 1 1 6.30215 93.69785 1.97173 4.541959
3 2 1.414214 24.48483 75.51517 1.878034 4.226797
4 3 1.732051 32.13283 67.86717 1.83166 4.078996
5 4 2 39.11672 60.88328 1.784498 3.933985
6 6 2.44949 56.97812 43.02188 1.633689 3.503992
7 8 2.828427 68.30769 31.69231 1.500954 3.164594
8 10 3.162278 79.84971 20.15029 1.304281 2.7212
9 12 3.464102 90.93196 9.068038 0.957513 2.085312
Figure 13: Drug released kinetic model of Ethyl cellulose Microcapsules (1:2 Ratio)
Table 14: Drug released kinetic model of Ethyl cellulose Microcapsules (1:3 Ratio)
46
S.
No.
Time
(hrs)
Square
route of
Time
% Drug
Released
% Drug
Unreleased
Log %
Drug
Unreleased
Cube root
of %Drug
Unreleased
1 0 0 0 100 2 4.641589
2 1 1 9.325397 90.6746 1.957486 4.492574
3 2 1.414214 22.96967 77.03033 1.886662 4.254879
4 3 1.732051 39.76937 60.23063 1.779817 3.919877
5 4 2 45.20129 54.79871 1.73877 3.798307
6 6 2.44949 56.17027 43.82973 1.641769 3.525789
7 8 2.828427 68.0872 31.9128 1.503965 3.171916
8 10 3.162278 74.61975 25.38025 1.404496 2.938768
9 12 3.464102 85.48047 14.51953 1.161952 2.439594
Figure 14: Drug released kinetic model of Ethyl cellulose Microcapsules (1:3 Ratio)
Table 15: Drug released kinetic model of Poly vinyl pyrrolidone Microcapsules
(1:2Ratio)
47
S.
No.
Time
(hrs)
Square
route of
Time
% Drug
Released
% Drug
Unreleased
Log %
Drug
Unreleased
Cube root
of %Drug
Unreleased
1 0 0 0 100 2 4.641589
2 1 1 7.410473 92.58953 1.966562 4.523979
3 2 1.414214 19.4721 80.5279 1.905946 4.318326
4 3 1.732051 25.47446 74.52554 1.872305 4.208252
5 4 2 33.99601 66.00399 1.81957 4.041321
6 6 2.44949 45.67349 54.32651 1.735012 3.787366
7 8 2.828427 60.02997 39.97003 1.601735 3.419098
8 10 3.162278 77.50209 22.49791 1.352142 2.823021
9 12 3.464102 94.5804 5.419598 0.733967 1.756531
Figure 15: Drug released kinetic model of PVP Microcapsules (1:2 Ratio)
Table 16: Drug released kinetic model of PVP Microcapsules (1:3 Ratio)
Zero order
48
S.
No.
Time
(hrs)
Square
route of
Time
% Drug
Released
% Drug
Unreleased
Log %
Drug
Unreleased
Cube root
of %Drug
Unreleased
1 0 0 0 100 2 4.641589
2 1 1 8.513588 91.48641 1.961357 4.505941
3 2 1.414214 21.87203 78.12797 1.892807 4.274994
4 3 1.732051 32.61051 67.38949 1.828592 4.069403
5 4 2 43.17027 56.82973 1.754576 3.844665
6 6 2.44949 55.09504 44.90496 1.652294 3.554388
7 8 2.828427 62.40998 37.59002 1.575073 3.349841
8 10 3.162278 66.55495 33.44505 1.524332 3.221889
9 12 3.464102 70.87951 29.12049 1.464199 3.076566
 Figure 16: Drug released kinetic model of PVP Microcapsules (1:3 Ratio)
Table 17: Drug released kinetic model of PVP Microcapsules (1:4 Ratio)
49
S.
No.
Time
(hrs)
Square
root of
Time
% Drug
Released
% Drug
Unreleased
Log %
Drug
Unreleased
Cube root
of %Drug
Unreleased
1 0 0 0 100 2 4.641589
2 1 1 4.404044 95.59596 1.98044 4.572424
3 2 1.414214 12.06766 87.93234 1.944149 4.44682
4 3 1.732051 13.98026 86.01974 1.934598 4.414343
5 4 2 18.15898 81.84102 1.912971 4.341672
6 6 2.44949 25.33411 74.66589 1.873122 4.210892
7 8 2.828427 33.6252 66.3748 1.822003 4.048875
8 10 3.162278 42.2692 57.7308 1.761408 3.864879
9 12 3.464102 51.21654 48.78346 1.688273 3.653907
Figure 17: Drug released kinetic model of PVP Microcapsules (1:4 Ratio)
Drug Release Kinetic Model Report
Table 18: Drug release kinetic model report
50
S.
No.
Type of
polymer
Ratio
Drug:Polymer
Correlation coefficient factor for drug
release profiles(R1)
Zero
order
First
order Higuchi
Hixon
Crowell
1. Ethyl
cellulose 1:1 0.9526 0.9673 0.9932 0.9876
2. -do- 1:2 0.9641 0.9602 0.9973 0.9910
3. -do- 1:3 0.9004 0.9857 0.9877 0.9884
4. PVP 1:2 0.9957 0.8470 0.9728 0.9315
5. -do- 1:3 0.8476 0.9734 0.9700 0.9556
6. -do- 1:4 0.9935 0.9872 0.9728 0.9924
The  above  table  shows  that,  the  release  kinetics  of  ethyl  cellulose  and  poly  vinyl
pyrrolidone  microcapsules  have  got  a  good  correlation  with  the  Higuchi  model.  The
results indicated that, various drug : polymer ratios in microcapsule preparation did not
change the release kinetics.
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7.6    Particle Size Analysis:
Table 19:  Particle size analysis of Ethyl cellulose micro capsules (1:1 Ratio)
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No.of particles
(Frequency) nd nd
2 nd3
1. 0-50 25 1 25 625 15625
2. 50-100 75 8 600 45000 3375000
3. 100-150 125 12 1500 187500 23437500
4. 150-200 175 34 5950 1041250 1.82x108
5. 200-250 225 28 6300 1417500 3.19 x108
6. 250-300 275 10 2750 756250 2.08 x108
7. 300-350 325 7 2275 739375 2.4 x108
∑n=100 ∑nd=19400
∑nd2=
4187500
∑nd3=
9.7625 x108
S.No.
Equation for
calculating diameter
mean
Type of mean Size parameter Frequency Mean diameter Value(micro meter) Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
-do-
-do-
-do-
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
194
204.6338
213.7242
233.1343
Refers to average particle Size
Refers to average particle surface area
Refers to average particle surface area
Refers to average particle specific
surface area
(inversely related)
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Table 20:  Particle size analysis of Ethyl cellulose micro capsules (1:2 Ratio)
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No.of particles
(Frequency) nd nd
2 nd3
1. 0-50 25 1 25 625 15625
2. 50-100 75 48 3600 270000 20250000
3. 100-150 125 18 2250 281250 35156250
4. 150-200 175 12 2100 367500 64312500
5. 200-250 225 8 1800 405000 91125000
6. 250-300 275 13 3575 983125 2.7 x108
∑n=100
∑nd=
13350
∑nd2=
2307500
∑nd3=
4.8121875
x108
S.No. Equation for calculatingdiameter mean
Type of
mean
Size
parameter Frequency
Mean
diameter
Value
(micro
meter)
Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
133.50
151.90
168.82
208.54
Refers to
average
particle
Size
Refers to
average
particle
surface
area
Refers to
average
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-do-
-do-
-do-
particle
surface
area
Refers to
average
particle
specific
surface
area
(inversely
related)
Table 21:  Particle size analysis of Ethyl cellulose micro capsules (1:3 Ratio)
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No. of particles
(Frequency) nd nd
2
nd3
1 0-50 25 1 25 625 15625
2 50-100 75 3 225 16875 1265625
3 100-150 125 22 2750 343750 42968750
4 150-200 175 5 875 153125 26796875
5 200-250 225 5 1125 253125 56953125
6 250-300 275 14 3850 1058750 2.91 x108
7 300-350 325 7 2275 739375 2.4 x108
8 350-400 375 8 3000 1125000 4.22 x108
9 400-450 425 7 2975 1264375 5.37 x108
10 450-500 475 11 5225 2481875 1.18 x108
11 500-550 525 9 4725 2480625 1.3 x108
12 550-600 575 8 4600 2645000 1.52 x109
∑n=100 ∑nd=31650
∑nd2=
12562500
∑nd3=
5620781250
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S.No. Eqn for calculatingdiameter mean
Type of
mean
Size
parameter Frequency
Mean 
diameter
Value
(µ meter) Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
-do-
-do-
-do-
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
316.5
354.4362
383.0589
447.4254
Refers to average particle Size
Refers to average particle surface area
Refers to average particle surface area
Refers to average particle specific surface area
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No. of particles
(Frequency) nd nd
2 nd3
1 0-50 25 0 0 0 0
2 50-100 75 4 300 22500 1687500
3 100-150 125 9 1125 140625 17578125
4 150-200 175 14 2450 428750 75031250
5 200-250 225 21 4725 1063125 2.39 x108
6 250-300 275 32 8800 2420000 6.66 x108
7 300-350 325 7 2275 739375 2.4 x108
8 350-400 375 8 3000 1125000 4.22 x108
9 400-450 425 5 2125 903125 3.84 x108
∑n=100 ∑nd=24800
∑nd2=
6842500
∑nd3=
20.45 x108
Table 22:  Particle size analysis of Poly vinyl pyrrolidone micro capsules (1:2 Ratio)
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S.No. Eqn for calculatingdiameter mean Type of mean Size parameter Frequency
Mean
diameter
Value
(µM) Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
-do-
-do-
-do-
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
248
261.5817
273.4625
298.8674
Refers to average particle
Size
Refers to average particle
surface area
Refers to average particle
surface area
Refers to average particle
specific surface area
Table 23:  Particle size analysis of Poly vinyl pyrrolidone micro capsules  (1:3 Ratio)
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No. of particles
(Frequency) nd nd
2 nd3
1 0-50 25 0 0 0 0
2 50-100 75 0 0 0 0
3 100-150 125 3 375 46875 5859375
4 150-200 175 22 3850 673750 1.18 x108
5 200-250 225 26 5850 1316250 2.96 x108
6 250-300 275 18 4950 1361250 3.74 x108
7 300-350 325 8 2600 845000 2.75 x108
8 350-400 375 4 1500 562500 2.11 x108
9 400-450 425 11 4675 1986875 8.44 x108
10 450-500 475 8 3800 1805000 8.57 x108
∑n=100 ∑nd=27600
∑nd2=
8597500
∑nd3=
29.81625 x108
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S.No. Eqn for calculatingdiameter mean Type of mean Size parameter Frequency
Mean
diameter
Value
(µ meter) Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
-do-
-do-
-do-
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
276.00
293.21
310.08
346.80
Refers to
average
particle Size
Refers to
average
particle
surface area
Refers to
average
particle
surface area
Refers to
average
particle
specific
surface area
Table 24:  Particle size analysis of Poly vinyl pyrrolidone micro capsules (1:4 Ratio)
S.No. Size Range(micro meter)
Mean size range
(micro meter)
No. of particles
(Frequency) nd nd
2 nd3
1 0-50 25 0 0 0 0
2 50-100 75 0 0 0 0
3 100-150 125 12 1500 187500 23437500
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4 150-200 175 39 6825 1194375 2.09 x108
5 200-250 225 27 6075 1366875 3.08 x108
6 250-300 275 3 825 226875 62390625
7 300-350 325 3 975 316875 1.03 x108
8 350-400 375 6 2250 843750 3.16 x108
9 400-450 425 6 2550 1083750 4.61 x108
10 450-500 475 4 1900 902500 4.29 x108
∑n=100 ∑nd=22900
∑nd2=
6122500
∑nd3=
19.110625 x108
S.No. Eqn for calculatingdiameter mean Type of mean Size parameter Frequency
Mean
diameter
Value
(µ meter) Comment
1
2
3
4
∑nd / ∑n
√ ∑nd2 / ∑n
3√ ∑nd3 / ∑n
∑nd3 / ∑nd2
Arithmetic
-do-
-do-
-do-
Length
Surface
Volume
Length
Number
-do-
-do-
Surface
Length
number
Surface
number
Volume
number
Volume
Surface
229.00
247.43
267.35
312.13
Refers to average particle
Size
Refers to average particle
surface area
Refers to average particle
surface area
Refers to average particle
specific surface area
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Particle Size Analysis:
Histogram of Microcapsules:
`
Figure 18: Histogram of particle size distribution for Ethylcellulose
Microcapsule (1:1 ratio)
Figure 19: Histogram of particle size distribution for Ethylcellulose
Microcapsule (1:2 ratios)
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Figure 20: Histogram of particle size distribution for Ethylcellulose
Microcapsule (1:3 ratios)
Figure 21: Histogram of particle size distribution for Polyvinylpyrrolidone
Microcapsule (1:2 ratios)
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Figure 22: Histogram of particle size distribution for Polyvinylpyrrolidone
Microcapsule (1:3 ratios)
Figure 23: Histogram of particle size distribution for Polyvinylpyrrolidone
Microcapsule (1:4 ratios)
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S.N
Type of
polymer
Ratio
Drug:
Polymer
Length
Diameter
(Mean)
Micrometer
Surface
number
(Mean)
Micrometer
Volume
number
(Mean)
Micrometer
Volume
surface
(Mean)
Micrometer
1
2
3
4
5
6
Ethylcellulose
-do-
-do-
PVP
-do-
-do-
1:1
1:2
1:3
1:2
1:3
1:4
194.00
133.50
316.50
248.00
276.00
229.00
204.63
151.90
354.54
261.58
293.21
247.43
213.72
168.82
383.05
273.46
310.08
267.35
233.13
201.54
447.42
298.86
346.80
312.13
Average Particle size of Microcapsules
Table 25:       Average particle size of microcapsules with different drug to polymer 
ratio.
In the above table it clearly shows that the average particle size of the microcapsules
increases  with decrease  in  the  drug to  polymer  ratio  except  1:2 ratio.  Similarly
specific surface area decreases in the same manner.
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7.7  DRUG-EXCIPIENT COMPATIBILITY STUDY BY FT-IR ANALYSIS
         
Fig. 24:  IR SPECTRA OF ACECLOFENAC WITH MAJOR PEAKS AT 3333.10,
2935.76, 1770.56, 1523.82, 1313.57, 850.64
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Fig. 25: IR SPECTRA OF PHYSICAL ADMIXTURE-1 WITH MAJOR
PEAKS OF ACECLOFENAC AT 3319.60, 2938.40, 1770.71, 1504.46, 1303.92,
860.28
*Physical admixture-1 = Aceclofenac + Ethyl Cellulose
Fig. 26: IR SPECTRA OF PHYSICAL ADMIXTURE-2 WITH MAJOR PEAKS
OF ACECLOFENAC AT 3319.60, 2937.68, 1770.71, 1506.46, 1303.92, 850.64
* Physical admixture-2 = Aceclofenac + PVP
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Fig. 27:  IR SPECTRA OF FORMULATION WITH MAJOR PEAKS OF
ACECLOFENAC AT 3319.60, 2937.68, 1772.64, 1511.21, 1303.92, 858.35
                               
  
 Fig. 28:  IR SPECTRA OF FORMULATION WITH MAJOR PEAKS OF
ACECLOFENAC AT 3319.60, 2932.40, 1770.71, 1503.38, 1301.99, 840.99
       Drug-Excipient compatibility was carried out by FT-IR analysis. Initially the IR
spectrum of pure drug was obtained. After that various admixtures of drug with
other excipients like Ethyl cellulose, Poly vinyl pyrrolidone and Formulations were
prepared and IR Spectra were obtained. The obtained spectra of physical admixtures
and  formulations  were  observed  for  major  peaks  of  drugs.  The  results  of  this
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observation  were  concluded  that  there  is  no  interaction  between  the  drug
(Aceclofenac) and other excipients. 
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8. SUMMARY AND CONCLUSION
Microencapsulation  has  received  considerable  attention  in  pharmaceutical  and
biomedical application, specifically achieving sustained release and controlled release
objectives.  Thus  it  is  an  useful  method  for  prolonging  drug  release  from dosage
forms, reducing adverse effects and to deliver drugs in a controlled manner.
In the present study, the drug, Aceclofenac is microencapsulated to prolong its action
in  the  form  of  microcapsules  and  to  explore,  which  polymer  is  suitable  for  this
purpose. Therefore, two different polymers with similar physicochemical properties
are chosen and used for the micro encapsulation with same procedure.
Preparation:
Solvent evaporation method may be used as a simple and common method to prepare
Aceclofenac sustained release microcapsules with different polymers.
When acetone is used as a solvent for the polymeric internal phase, the ethyl cellulose
is able to encapsulate and it is failed, when dichloromethane is used as a solvent. The
expected reason for the failure of micro encapsulation with dichloromethane is may
be due to difference in volatility between the two solvents. The drug is effectively
encapsulated with polyvinylpyrrolidone,  when the external  phase containing liquid
paraffin.
The selection of best polymer is based on the observation of the following four results
of evaluation of microcapsules.
Encapsulation efficiency: Ethyl cellulose is able to microencapsulate the drug, when
its concentration is between (5-15) %w/v in solvent acetone, whereas PVP polymer is
able to micro encapsulate, when its concentration is 10 % w/v or more in acetone.
Encapsulation efficiency of ethyl cellulose microcapsules with 1:1 drug to polymer
ratio is 96.01%, with 1:2 ratio is 94.45% and with 1:3 ratio is 80.40%. Since the
encapsulation efficiency decreases with increase in the ratio, it can be considered that
1:1 ratio is the comparatively good ratio. Similarly, encapsulation efficiency of PVP
microcapsules with 1:2 ratio is 92.50%, with 1:3 ratio is 60.10% and with 1:4 ratio
46.44%. In this case 1:2 ratio also showed good encapsulation efficiency than 1:3 and
1:4 ratios. So it can be considered as an optimum ratio.
The  amount  of  drug  loaded  and  the  encapsulation  efficiency  of  microcapsules
prepared under various formulation conditions are depicted in formulation table.
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As expected, increasing the amount of polymer in drug : polymer ratio and increasing
the polymer concentration in internal phase caused a decrease in the drug content in
microcapsules in both cases.
It seems that, increasing the drug: polymer ratio more than 1: 4 in polymeric solution
leads to higher internal phase viscosity, which in turn results in the formation of larger
particles.  It  should  be  mentioned  that,  microcapsules  formation  was  found  to  be
impossible, probably due to high viscosity of drug: polymer solution prepared at the
ratio of more than 1: 4 and dispersibililty of internal phase into continuous phase.
Dissolution Profile:
Ethylcellulose  and  Polyvinylpyrrolidone  (PVP)  microcapsule  reduces  the  inherent
dissolution rate of the pure drug by about 16 times i.e. the time taken to dissolve 90 %
of the pure drug is 45 minutes and it is increased to 11-12 hrs in case of Ethylcellulose
microcapsule and to 11-13 hrs in case of Polyvinylpyrrolidone microcapsule. 
It was observed that the release kinetics of ethyl cellulose and poly vinyl pyrrolidone
microcapsules  have  got  a  good  correlation  with  the  Higuchi  model.  The  results
indicated  that,  various  drug  :  polymer  ratios  in  microcapsule  preparation  did  not
change the release kinetics.
The time taken for 90 % release of the drug from ethylcellulose microcapsules with
1:1 drug-polymer ratio was 11.85 hrs, with 1:2 ratio was 10.90 hrs, while, with 1:3
ratio  was  11.18  hrs.  Therefore,  decrease  in  dissolution  rate  of  different  drug  to
polymer ratio was of the following order: 1:2 > 1:3 > 1:1. Similarly the time taken for
90% release of the drug from PVP microcapsule with 1:2 drug to polymer ratio was
11.51 hrs, with 1:3 ratio was 12.61 hrs while, with 1:4 ratio was 12.35 hrs. Therefore,
decrease in dissolution rate of different drug to polymer ratio was of the following
order: 1:2 > 1:4 > 1:3.
The  possible  expected  result  for  this  release  profile  with  both  the  polymers  was
mainly  focused  on  the  difference  in  particle  size  between  the  ratios  of  the  same
polymer.  As  it  was  observed  that  the  diameter-volume-surface  for  ethyl  cellulose
microcapsule  with  1:1  drug  to  polymer  ratio  was  233.13  µm,  with 1:2  ratio  was
201.54 µm and with 1:3 ratio was 447.42 µm. So, specific surface area was 1:2 > 1:1
> 1:3.  Similarly,  diameter-volume-surface  for  PVP microcapsule  with 1:2 drug to
polymer ratio was 298.86 µm, with 1:3 ratio was 346.80 µm and with 1:4 ratio was
312.13µm. So, specific surface area was 1:2 > 1:4 > 1:3 and hence the drug release
rate follows the same order of release.
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Particle size analysis: It  was observed the mean particle size of the microcapsule
increase  with  increase  in  polymer  concentration,  but  increasing  the  stirring  speed
resulted in a decrease in the mean particle size of microcapsules.
Histogram shows that, ethyl cellulose microcapsules with drug to polymer ratio 1:1
and 1:2 are uniform in size and shape with narrow range of distribution, whereas, PVP
microcapsules are irregular shapes with wide range of size distribution.
FTIR study:  Under IR  study the functional  group and finger  print  region,  all  the
peaks of the drug, polymer and drug loaded microcapsules were correlated with each
other. 
Thus, from the figure it is observed that, there was no significant difference in the IR
spectra of pure aceclofenac and drug loaded microcapsules. The characteristic N-H
stretching of secondary amine, C-H stretching of pure drug was unchanged in case of
microcapsules. The results suggest drug stability during the encapsulation process.
In view of the project work, it is concluded that Microencapsulation of Aceclofenac
drug with Ethylcellulose in 1:1 ratio may be considered as best form for drug delivery
in terms of release profile, encapsulation efficiency and particle size distribution.
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